What happened
BillionToOne, Inc. (NASDAQ: BLLN) said Chief Technology Officer and director David Tsao sold 20,000 shares on 2026-10-05. The shares sold in multiple transactions from $105.56 to $110.09 each, and the Form 4 puts the total at about $2.16 million. The filing also shows Tsao exercised two 10,000-share option blocks at $2.8 a share on the same date. The options were fully vested and exercisable, according to the filing. All reported transactions took place on 2026-10-05.
Those exercises left Tsao with 21,000 shares before the sales started, and the last sale left Tsao with 1,000 shares. The form says the trades were made under a Rule 10b5-1 trading plan adopted on June 5, 2026.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 20,000 shares | SEC Form 4 | |
| Sale price | $105.56 to $110.09 per share | SEC Form 4 | |
| Sale value | about $2.16 million | SEC Form 4 | |
| Shares held after sale | 1,000 shares | SEC Form 4 | |
| Shares sold as a share of pre-sale holdings | 95.2% | Calculated from SEC Form 4 |
Why it matters
OptimistFi's case is that BillionToOne works if its prenatal and oncology molecular tests keep winning orders and reimbursement while scale turns that volume into cash generation. This filing is mixed for that case because a senior insider reduced direct ownership, but the trade was tied to a prearranged plan. OptimistFi calculates the 20,000 shares sold were about 95.2% of the 21,000 shares Tsao held before the sale.
That means the report leaves Tsao with a small direct stake of 1,000 shares, while the same filing shows option exercises and sales on one date. The result is a trading snapshot, and it gives investors a clear ownership baseline for later filings. Investors can track that baseline closely from here.
Related: BillionToOne, Inc. (NASDAQ: BLLN) Stock Is Up 12%: The Investment Case
What's next
The next quarterly report is the next scheduled check on whether the business case keeps building for now. A report that shows continued order growth or reimbursement progress would strengthen the case, while further insider sales would keep the signal mixed. Until then, the filing mainly establishes that the chief technology officer and director sold most of the shares Tsao controlled before the trade under a Rule 10b5-1 plan.
More from OptimistFi
- BLLN stock: the BillionToOne thesis, its status and the next test to watch
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Form 4 for BillionToOne, Inc. reporting David Tsao's sales, option exercises and Rule 10b5-1 plan.
Read the full OptimistFi thesis on BillionToOne, Inc.: https://optimistfi.com/stocks/BLLN
See what would break the BillionToOne, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full BillionToOne, Inc. investment case, its status and the next test to watch live on the BillionToOne, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
